<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334006</url>
  </required_header>
  <id_info>
    <org_study_id>15-167</org_study_id>
    <nct_id>NCT03334006</nct_id>
  </id_info>
  <brief_title>Personalised Medicine With Pentaglobin® Compared With Standard of Care for Treatment of Peritonitis After Infectious Source Control</brief_title>
  <acronym>PEPPER</acronym>
  <official_title>Personalised Medicine With Pentaglobin® Compared With Standard of Care for Treatment of Peritonitis After Infectious Source Control (the PEPPER Trial): a Prospective, Randomised, Controlled, Open Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the adjuvant Immuneglobulins G, A and M (IgGAM)
      treatment for:

        1. An improvement of the outcome for the patient's peritonitis. This will be investigated
           by using scores such as the multiple organ failure (MOF) and Sequential Organ Failure
           Assessment (SOFA) scores as well as survival data.

        2. Identification of biomarkers [Ig level, procalcitonin (PCT), interleukin-6 (IL 6), Human
           Leukocyte Antigen - antigen D Related (HLA DR), nuclear factor
           kappa-light-chain-enhancer of activated B cells (NF kB1), adrenomedullin (ADM), pathogen
           spectrum], to identify patient subpopulations that profit most from treatment with
           IgGAM. Such patients will comprise the basis for a further study, which will be a
           randomised, controlled, double-blind trial (RCT) to demonstrate the value of this
           treatment.

        3. Furthermore, these biomarkers are expected to help with developing a &quot;personalised&quot;
           adjuvant therapy with IgGAM in the indication of peritonitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test the adjuvant IgGAM treatment for:

        1. An improvement of the outcome for the patient's peritonitis. This will be investigated
           by using scores such as the multiple organ failure and SOFA scores as well as survival
           data.

        2. Identification of biomarkers (Ig level, PCT, IL 6, HLA DR, Nf kB1, ADM, pathogen
           spectrum), to identify patient subpopulations that profit most from treatment with
           IgGAM. Such patients will comprise the basis for a further study, which will be a
           randomised, controlled, double-blind trial (RCT) to demonstrate the value of this
           treatment.

        3. Furthermore, these biomarkers are expected to help with developing a &quot;personalised&quot;
           adjuvant therapy with IgGAM in the indication of peritonitis.

      The control group will receive standard-of-care treatment, i.e., the IgGAM is an add-on
      treatment in this study.

      The active study treatment is IgGAM (Pentaglobin®). IgGAM is administered by continuous
      infusion over 5 days at a dose level of 0.4 ml per kg body weight per hour, until a total
      dose of 7 ml/kg on that day has been reached; administration will then be stopped and
      recommenced on the following day, until administration has been completed for 5 consecutive
      days.

      Primary target variable The relative number of patients whose MOF score improves by 0.8
      points on Day 7 (i.e., percentage of 'responders'). The primary analysis will be performed
      with the per protocol population (see below).

      The MOF score is determined in the morning, with the following scoring for each organ (lungs,
      heart, kidneys, liver, blood): normal function, 0; dysfunction, 1; individual organ failure,
      2. An aggregate score greater than 4 implies multi-organ failure. Patients who die will be
      assigned the maximum score of 10 and will be included in the population assessment.

      Secondary target variables

        -  Overall 28-day survival,

        -  Overall 90-day survival,

        -  MOF score on Day 5,

        -  Relative number of patients with MOF (i.e., &gt; 4 MOF points) on Day 7. Additional study
           variables

        -  Time course of the biomarkers (PCT, IL 6, HLA DR, ADM, Immuneglobulins M, G, A), the
           SOFA score, the Mannheim Peritonitis Index, the surrogate variables for organ
           dysfunction and survival according to Heyland et al. 2011 and vital signs.

        -  Influence of the biomarkers NF kB1, ADM and pathogen spectrum upon the outcome for the
           patient.

        -  Comparison of the MOF score with other scores, such as the SOFA score, for assessment of
           organ dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The control group will receive standard-of-care treatment, i.e., the IgGAM is an add-on treatment in this study.
The active study treatment is IgGAM (Pentaglobin®). The preparation to be provided contains (per ml solution) 50 mg human plasma proteins, of which &gt;95% are immunoglobulins: IgM 6 mg, IgA 6 mg and IgG 38 mg. The IgG subclass distribution is IgG1 ~63%, IgG2 ~26%, IgG3 ~4%, IgG4 ~7%. IgGAM is administered by continuous infusion over 5 days at a dose level of 0.4 ml per kg body weight per hour, until a total dose of 7 ml/kg on that day has been reached; administration will then be stopped and recommenced on the following day, until administration has been completed for 5 consecutive days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative number of patients whose MOF score improves by 0.8 points on Day 7 (i.e., percentage of 'responders') [%]</measure>
    <time_frame>7 days</time_frame>
    <description>The relative number of patients whose MOF score improves by 0.8 points on Day 7 (i.e., percentage of 'responders').
The MOF score is determined in the morning, with the following scoring for each organ (lungs, heart, kidneys, liver, blood): normal function, 0; dysfunction, 1; individual organ failure, 2. An aggregate score greater than 4 implies multi-organ failure. Patients who die will be assigned the maximum score of 10 and will be included in the population assessment.
Day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of survivers on day 28 [-]</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of the Overall 28-day survival.
Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of survivers on day 90 [-]</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation of the Overall 90-day survival.
Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOF Score on day 5 [-]</measure>
    <time_frame>5 days</time_frame>
    <description>MOF Score on day 5
Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative number of patients with MOF (i.e., &gt; 4 MOF points) on Day 7 [%]</measure>
    <time_frame>7 days</time_frame>
    <description>Relative number of patients with MOF (i.e., &gt; 4 MOF points) on Day 7 [%]
Day 7</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peritonitis</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>A: Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Pentaglobin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care + Pentaglobin®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentaglobin®</intervention_name>
    <description>Standard of Care + Pentaglobin®</description>
    <arm_group_label>B: Pentaglobin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Peritonitis.

          2. Time of source control intervention: within 6 hours of determination of the indication
             (defined as the time of placing the patient on the list for operation or minimally
             invasive measure).

          3. Sepsis and septic shock (according to the current sepsis guideline [Rhodes 2017]).

          4. SOFA score of 8 or above.

          5. IL 6 level of 1000 pg/ml or above.

          6. Antibiotic treatment begun within 12 hours after entry to the ICU.

          7. Written informed consent by the patient or if appropriate by his/her legal
             representative or the consulting physician.

        Exclusion criteria

          1. Life expectancy less than 90 days because of medical circumstances than are not
             related to the patient's peritonitis or sepsis / septic shock.

          2. Pregnancy, breast-feeding.

          3. Age below 18 years.

          4. Known chronic kidney insufficiency requiring dialysis (creatinine ≥ 3.4 mg/dl or
             creatinine clearance ≤ 30 mL/min/1.73 m2).

          5. Pancreatitis or mediastinitis.

          6. Body mass index &gt; 40 kg/m2.

          7. Presence of any counter-indication against the study medication.

          8. Participation in any other mediation study within the previous 30 days.

          9. A dependency or a professional relationship to the sponsor or the investigator.

         10. Commitment of the patient to any resident institution by order of any court or
             authority.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gernot Marx, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RWTH Aachen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kalvelage Christina, M. Sc.</last_name>
    <phone>0241 80 36485</phone>
    <email>ckalvelage@ukaachen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gernot Marx, Prof. Dr. med.</last_name>
      <email>gmarx@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Tim-Philipp Simon, Dr. med.</last_name>
      <email>tsimon@ukaachen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kujath P., Rodloff Peritonitis UNI-MED, 2001 ISBN 3-8999-549-5</citation>
  </reference>
  <reference>
    <citation>Chang HJ, Lynm C, Glass RM. JAMA patient page. Sepsis. JAMA. 2010 Oct 27;304(16):1856. doi: 10.1001/jama.304.16.1856.</citation>
    <PMID>20978264</PMID>
  </reference>
  <reference>
    <citation>Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J; Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001 Aug 1;164(3):396-402.</citation>
    <PMID>11500339</PMID>
  </reference>
  <reference>
    <citation>Heyland DK, Muscedere J, Drover J, Jiang X, Day AG; Canadian Critical Care Trials Group. Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials. Crit Care. 2011;15(2):R98. doi: 10.1186/cc10110. Epub 2011 Mar 18.</citation>
    <PMID>21418560</PMID>
  </reference>
  <reference>
    <citation>Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000 Apr;28(4):977-83.</citation>
    <PMID>10809269</PMID>
  </reference>
  <reference>
    <citation>Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 Suppl 1:S57-61. Review.</citation>
    <PMID>10984072</PMID>
  </reference>
  <reference>
    <citation>Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, Cupa M, Cohen Y. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med. 2006 Jan;34(1):102-7.</citation>
    <PMID>16374163</PMID>
  </reference>
  <reference>
    <citation>Monneret G, Doche C, Durand DV, Lepape A, Bienvenu J. Procalcitonin as a specific marker of bacterial infection in adults. Clin Chem Lab Med. 1998 Jan;36(1):67-8.</citation>
    <PMID>9594089</PMID>
  </reference>
  <reference>
    <citation>Brunkhorst FM. [Sepsismarker--what is useful?]. Dtsch Med Wochenschr. 2008 Nov;133(48):2512-5. doi: 10.1055/s-0028-1100949. Epub 2008 Nov 19. Review. German.</citation>
    <PMID>19021084</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. Epub 2006 Apr 7.</citation>
    <PMID>16603606</PMID>
  </reference>
  <reference>
    <citation>Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253-78. Review.</citation>
    <PMID>2188664</PMID>
  </reference>
  <reference>
    <citation>Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004 Nov;32(11):2173-82.</citation>
    <PMID>15640628</PMID>
  </reference>
  <reference>
    <citation>Küster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, Geiger R, Lipowsky G, Simbruner G. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet. 1998 Oct 17;352(9136):1271-7.</citation>
    <PMID>9788457</PMID>
  </reference>
  <reference>
    <citation>Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009 Oct 1;180(7):640-8. doi: 10.1164/rccm.200903-0363OC. Epub 2009 Jul 9.</citation>
    <PMID>19590022</PMID>
  </reference>
  <reference>
    <citation>Schefold JC, von Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, Volk HD, Reinke P. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock. 2007 Oct;28(4):418-25.</citation>
    <PMID>17558345</PMID>
  </reference>
  <reference>
    <citation>Bermejo-Martín JF, Rodriguez-Fernandez A, Herrán-Monge R, Andaluz-Ojeda D, Muriel-Bombín A, Merino P, García-García MM, Citores R, Gandía F, Almansa R, Blanco J; GRECIA Group (Grupo de Estudios y Análisis en Cuidados Intensivos). Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med. 2014 Oct;276(4):404-12. doi: 10.1111/joim.12265. Epub 2014 May 29.</citation>
    <PMID>24815605</PMID>
  </reference>
  <reference>
    <citation>Giamarellos-Bourboulis EJ, Apostolidou E, Lada M, Perdios I, Gatselis NK, Tsangaris I, Georgitsi M, Bristianou M, Kanni T, Sereti K, Kyprianou MA, Kotanidou A, Armaganidis A; Hellenic Sepsis Study Group. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care. 2013 Oct 21;17(5):R247. doi: 10.1186/cc13073.</citation>
    <PMID>24144038</PMID>
  </reference>
  <reference>
    <citation>Tamayo E, Fernández A, Almansa R, Carrasco E, Goncalves L, Heredia M, Andaluz-Ojeda D, March G, Rico L, Gómez-Herreras JI, de Lejarazu RO, Bermejo-Martin JF. Beneficial role of endogenous immunoglobulin subclasses and isotypes in septic shock. J Crit Care. 2012 Dec;27(6):616-22. doi: 10.1016/j.jcrc.2012.08.004. Epub 2012 Oct 22.</citation>
    <PMID>23089676</PMID>
  </reference>
  <reference>
    <citation>Koo DJ, Zhou M, Chaudry IH, Wang P. The role of adrenomedullin in producing differential hemodynamic responses during sepsis. J Surg Res. 2001 Feb;95(2):207-18. Review.</citation>
    <PMID>11162047</PMID>
  </reference>
  <reference>
    <citation>Wang P, Ba ZF, Cioffi WG, Bland KI, Chaudry IH. The pivotal role of adrenomedullin in producing hyperdynamic circulation during the early stage of sepsis. Arch Surg. 1998 Dec;133(12):1298-304.</citation>
    <PMID>9865646</PMID>
  </reference>
  <reference>
    <citation>Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care. 2014 Feb 17;18(1):R34. doi: 10.1186/cc13731.</citation>
    <PMID>24533868</PMID>
  </reference>
  <reference>
    <citation>Ueda S, Nishio K, Minamino N, Kubo A, Akai Y, Kangawa K, Matsuo H, Fujimura Y, Yoshioka A, Masui K, Doi N, Murao Y, Miyamoto S. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med. 1999 Jul;160(1):132-6.</citation>
    <PMID>10390390</PMID>
  </reference>
  <reference>
    <citation>Adamzik M, Frey UH, Möhlenkamp S, Scherag A, Waydhas C, Marggraf G, Dammann M, Steinmann J, Siffert W, Peters J. Aquaporin 5 gene promoter--1364A/C polymorphism associated with 30-day survival in severe sepsis. Anesthesiology. 2011 Apr;114(4):912-7. doi: 10.1097/ALN.0b013e31820ca911.</citation>
    <PMID>21427539</PMID>
  </reference>
  <reference>
    <citation>Zhu Y, Qiu HB, Liu JT, Wang Y, Lin HY, Xu Y, Jiang L, Shi Y, Zhu X, Ning B, Cheng R, Xie ZY, Ma PL. [Effect of endothelial nitric oxide synthase gene polymorphisms upon disease severity and outcome in septic patients]. Zhonghua Yi Xue Za Zhi. 2010 Apr 6;90(13):906-11. Chinese.</citation>
    <PMID>20646511</PMID>
  </reference>
  <reference>
    <citation>Thair SA, Walley KR, Nakada TA, McConechy MK, Boyd JH, Wellman H, Russell JA. A single nucleotide polymorphism in NF-κB inducing kinase is associated with mortality in septic shock. J Immunol. 2011 Feb 15;186(4):2321-8. doi: 10.4049/jimmunol.1002864. Epub 2011 Jan 21.</citation>
    <PMID>21257964</PMID>
  </reference>
  <reference>
    <citation>Beyer K, Menges P, Keßler W, Heidecke CD. [Pathophysiology of peritonitis]. Chirurg. 2016 Jan;87(1):5-12. doi: 10.1007/s00104-015-0117-6. Review. German.</citation>
    <PMID>26661744</PMID>
  </reference>
  <reference>
    <citation>Rodríguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005 Apr;23(4):298-304.</citation>
    <PMID>15803051</PMID>
  </reference>
  <reference>
    <citation>Cavazzuti I, Serafini G, Busani S, Rinaldi L, Biagioni E, Buoncristiano M, Girardis M. Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med. 2014 Dec;40(12):1888-96. doi: 10.1007/s00134-014-3474-6. Epub 2014 Sep 13.</citation>
    <PMID>25217146</PMID>
  </reference>
  <reference>
    <citation>Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090. doi: 10.1002/14651858.CD001090.pub2. Review.</citation>
    <PMID>24043371</PMID>
  </reference>
  <reference>
    <citation>Janssens U. [Treatment of sepsis and septic shock with immunoglobulins]. Dtsch Med Wochenschr. 2014 Jan;139(5):178. doi: 10.1055/s-0032-1329177. Epub 2014 Jan 21. German.</citation>
    <PMID>24449349</PMID>
  </reference>
  <reference>
    <citation>Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Gründling M, John S, Kern W, Kreymann G, Krüger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stüber F, Weiler N, Weimann A, Werdan K, Welte T; German Interdisciplinary Association for Intensive and Emergency Care Medicine; German Sepsis Society. [Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)]. Anaesthesist. 2010 Apr;59(4):347-70. doi: 10.1007/s00101-010-1719-5. German.</citation>
    <PMID>20414762</PMID>
  </reference>
  <reference>
    <citation>Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrère JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg. 1985 Oct;120(10):1109-15.</citation>
    <PMID>4038052</PMID>
  </reference>
  <reference>
    <citation>Lefering R, Goris RJ, van Nieuwenhoven EJ, Neugebauer E. Revision of the multiple organ failure score. Langenbecks Arch Surg. 2002 Apr;387(1):14-20. Epub 2002 Jan 31.</citation>
    <PMID>11981679</PMID>
  </reference>
  <reference>
    <citation>Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM, Reinhart K, Selvakumar N, Levy MM. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med. 2015 Mar;43(3):567-73. doi: 10.1097/CCM.0000000000000742.</citation>
    <PMID>25479113</PMID>
  </reference>
  <reference>
    <citation>Weigelt JA. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med. 2007 Aug;74 Suppl 4:S29-37. Review.</citation>
    <PMID>17847176</PMID>
  </reference>
  <reference>
    <citation>Wong PF, Gilliam AD, Kumar S, Shenfine J, O'Dair GN, Leaper DJ. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004539. Review.</citation>
    <PMID>15846719</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Laterre PF, Russell JA, Bergmann A, Gattinoni L, Gayat E, Harhay MO, Hartmann O, Hein F, Kjolbye AL, Legrand M, Lewis RJ, Marshall JC, Marx G, Radermacher P, Schroedter M, Scigalla P, Stough WG, Struck J, Van den Berghe G, Yilmaz MB, Angus DC. Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure. J Intensive Care. 2016 Mar 31;4:24. doi: 10.1186/s40560-016-0151-6. eCollection 2016. Review.</citation>
    <PMID>27034779</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pentaglobin®</keyword>
  <keyword>Personalised Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin A</mesh_term>
    <mesh_term>Immunoglobulin M</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

